Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Dose-Escalation Study of LY2157299 Monotherapy in Patients With Solid Tumors
jRCT2080221965Phase 1
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of galunisertib in Nonhematologic neoplasms (2 arms), sponsored by Eli Lilly and Company.
02
Drugs
galunisertib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2080221965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221965.